1. Kim L, Markovina S, Van Nest SJ, Eisaman S, Santanam L, Sullivan JM, Dominello M, Joiner MC, Burmeister J. Three discipline collaborative radiation therapy (3DCRT) special debate: Equipment development is stifling innovation in radiation oncology. J Appl Clin Med Phys. 2019 May 25. doi: 10.1002/acm2.12620. [Epub ahead of print] No abstract available. PMID: 31127693
  2. Lin AJ, Samson P, Zoberi J, Garcia-Ramirez J, Williamson JF, Markovina S, Schwarz J, Grigsby PW. Concurrent chemoradiation for cervical cancer: Comparison of LDR and HDR brachytherapy. Brachytherapy. 2019 May – Jun;18(3):353-360. doi: 10.1016/j.brachy.2018.11.008. Epub 2019 Apr 7. PMID: 30971370
  3. Patel RB, Baniel CC, Sriramaneni RN, Bradley K,Markovina S, Morris ZS. Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. Brachytherapy. 2019 Mar – Apr;18(2):240. doi: 10.1016/j.brachy.2019.01.004. No abstract available. PMID: 30914131
  4. Lin AJ, Ma S, Markovina S, Schwarz J, Mutch DG, Powell MA, Grigsby PW. Clinical outcomes after isolated pelvic failure in cervical cancer patients treated with definitive radiation. Gynecol Oncol. 2019 Jun;153(3):530-534. doi: 10.1016/j.ygyno.2019.03.104. Epub 2019 Mar 21. PMID: 30905434
  5. Lin A, Ma S, Dehdashti F, Markovina S, Schwarz J, Siegel B, Powell M, Grigsby P. Detection of distant metastatic disease by positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) at initial staging of cervical carcinoma. Int J Gynecol Cancer. 2019 Mar;29(3):487-491. doi: 10.1136/ijgc-2018-000108. Epub 2019 Feb 9. PMID: 30739082
  6. Lin AJ, Hassanzadeh C, Markovina S, Schwarz J, Grigsby P. Brachytherapy and survival in small cell cancer of the cervix and uterus. Brachytherapy. 2019 Mar – Apr;18(2):163-170. doi: 10.1016/j.brachy.2018.11.006. Epub 2018 Dec 15. PMID: 30563743
  7. Lin AJ, Samson P, DeWees T, Henke L, Baranski T, Schwarz J, Pfeifer J, Grigsby P, Markovina S. A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer. Cancer Med. 2019 Jan;8(1):437-446. doi: 10.1002/cam4.1857. Epub 2018 Dec 14. PMID: 30552739
  8. Lin AJ, Kidd E, Dehdashti F, Siegel BA, Mutic S, Thaker PH, Massad LS, Powell MA, Mutch DG, Markovina S, Schwarz J, Grigsby PW. Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1088-1097. doi: 10.1016/j.ijrobp.2018.11.012. Epub 2018 Nov 14. PMID: 30445171
  9. Patel RB, Baniel CC, Sriramaneni RN, Bradley K, Markovina S, Morris ZS. Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. Brachytherapy. 2018 Nov – Dec;17(6):995-1003. doi: 10.1016/j.brachy.2018.07.004. Epub 2018 Aug 2. Review. Erratum in: Brachytherapy. 2019 Mar – Apr;18(2):240. PMID: 30078541
  10. Huynh M, Pak C, Markovina S, Callander NS, Chng KS, Wuerzberger-Davis SM, Bakshi DD, Kink JA, Hematti P, Hope C, Asimakopoulos F, Rui L, Miyamoto S. “Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-kB activity and increases drug resistance in multiple myeloma.” J Biol Chem, 2017 Dec 26. pii: jbc.RA117.000667. doi: 10.1074/jbc.RA117.000667. [Epub ahead of print], PMID: 29279332
  11. Perry Grigsby, M.D., Adnan Elhammali, M.D., Ph.D., Fiona Ruiz, B.S., Stephanie Markovina, M.D., Ph.D, Michael Mclellan, Ph.D., Christopher Miller, Ph.D., Anupama Chundury, M.D., Anh L. Ta, B.S., Ramachandran Rashmi, Ph.D., John D. Pfeifer, M.D., Ph.D., Robert Fulton, Ph.D., Todd DeWees, Ph.D., Julie K. Schwarz, M.D., Ph.D., “Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer.” Oncotarget, 2017 Dec 23;9(3):4061-4073.
  12. Stephanie Markovina, Songyan Wang, Lauren Henke MD, Clifford Luke PhD, Stephen Pak PhD, Todd DeWees PhD, John Pfeifer MD/PhD, Julie Schwarz MD/PhD, Xiaowei Wang PhD, David Mutch MD, Matthew Powell MD, Barry Siegel MD, Farrokh Dehdashti MD, Gary Silverman MD/PhD, and Perry Grigsby MD. “Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer.” British Journal of Cancer, 2018 Jan;118(1):72-78. doi: 10.1038/bjc.2017.390.
  13. Stephanie Markovina, Marshall Meeks, Shahed Badiyan, Joel Vetter, Hiram Gay, Alethea Paradis, Jeff Michalski, Gurdarshan Sandhu,“Superior Metastasis-Free Survival for Patients with High Risk Prostate Cancer Treated with Definitive Radiation Therapy Compared to Radical Prostatectomy; A Propensity Score Matched Analysis.” In press, Advances in Radiation Oncology, DOI: https://doi.org/10.1016/j.adro.2017.12.001.
  14. Stephanie Markovina, Fady Youssef, Amit Roy, Sonya Aggarwal, Shariq Khwaja, Todd DeWees, Benjamin Tan, Stephen Hunt, Robert Myerson, Daniel Chang, Parag Parikh and Jeffrey Olsen, “Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.” Int J Radiat Oncol Biol Phys. 2017 Oct 1; 99(2):417-426. PMID: 28871992.
  15. Re-I Chin, B.A., Yuan James Rao, M.D., Caressa Hui, B.S. David G. Mutch, M.D., Matthew A. Powell, M.D., Julie K. Schwarz, M.D. Ph.D., Perry W. Grigsby, M.D., Stephanie Markovina M.D., Ph.D., “Improved Survival with Definitive Chemoradiation Compared to Definitive Radiation Alone in Squamous Cell Carcinoma of the Vulva: A Review of the National Cancer Database.” Gynecol Oncol. 2017 Sep;146(3):572-579.
  16. Michael L Cardenas, Chris R Spencer, Stephanie Markovina, Todd A DeWees, Steven Hunt, Robert J Myerson, M Silviera, R Jain, Parag J Parikh, Benjamin Tan, Perry W Grigsby, Faroukh Dehdashti, Jeffrey R Olsen, “Quantitative FDG-PET/CT Predicts Local Recurrence and Survival for Squamous Cell Carcinoma of the Anus.” Adv Radiat Oncol. 2017 Apr 29;2(3):281-287.
  17. Shariq Khwaja, Amit Roy, Stephanie Markovina, Todd DeWees, Stephen Hunt, Benjamin Tan, Robert Myerson, Jeffrey Olsen and Parag Parikh. “Quality of Life Outcomes From a Phase 2 Trial of Short-Course Radiation Therapy Followed by FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer.” Int J Radiat Oncol Biol Phys.2016 Aug 1:95(5):1429-38.
  18. Stephanie Markovina, Fenghai Duan, Bradley S. Snyder, Barry A. Siegel, Mitchell Machtay, Jeffrey Bradley, “Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.” Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):597-605.
  19. Stephanie Markovina, Jeff Michalski. “Unfair Comparisons Lead to Unwarranted Conclusions — Can Treatment Modalities for Localized Prostate Cancer Truly be Compared without Bias?” Invited Point/Counterpoint series, Brachytherapy. 2015 Nov-Dec;14(6):756-60.
  20. Stephanie Markovina, Perry W. Grigsby, Julie K Schwarz, Todd DeWees, Jeffrey F. Moley, Barry A. Siegel, Stephanie M. Perkins. “Treatment Approach, Surveillance and Outcome of Well-differentiated Thyroid Cancer in Childhood and Adolescence,” Thyroid. 2014 Jul;24(7):1121-6.
  21. Stephanie Markovina, Débora Cristina Weschenfelder, Hiram Gay, Todd DeWees, Audrey McCandless, Bethany Carey, Nels Knutson, Jeff Michalski. “Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer.” Pract Radiat Oncol. 2014;4(6):430-6.
  22. Shahed N Badiyan, Stephanie Markovina, Joseph Simpson, Clifford G Robinson, Todd DeWees, David D Tran, Gerald Linette, Rohan Jalalizadeh, Ralph Dacey, Keith M Rich, Michael R Chicoine, Joshua L Dowling, Eric C Leuthardt, Gregory J Zipfel, Albert H Kim, “Radiation Therapy Dose-Escalation for Glioblastoma Multiforme in the Era of Temozolomide.” Int J Radiation Oncol Biol Phys.. 2014 Sep; S0360-3016(14)03493-2.
  23. Natalie Callander, Stephanie Markovina, Jens Eickhoff, Paul Hutson, Toby Campbell, Peiman Hematti, Ronald Go, Robert Hegeman, Walter Longo, Eliot Williams, Fotis Asimakopoulos, Shigeki Miyamoto, “Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network.” Cancer Chemother Pharmacol. 2014 Oct;74(4):875-82.
  24. Stephanie Markovina, Natalie Callendar, Shelby O’Connor, Guangwu Xu, Yufang Shi, Catherine Leith, KyungMann Kim, Parul Trivedi, Peiman Hematti, Shigeki Miyamoto, “Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.” Molecular Cancer, 2010 Jul 6;9:176.
  25. William T Simonson, Stephanie Markovina, William J Grossman, Mary A Lokuta, Ashley T Doan, Christine M Seroogy, Anna Huttenlocher, “Common variable immunodeficiency with regulatory T-cell deficiency treated with rapamycin.” Ann Allergy Asthma Immunol, 2009 Feb;102(2):170-1.
  26. Stephanie Markovina, Natalie S Callander, Shelby L O’Connor, Jihoon Kim, Jae E Werndli, Martha Raschko, Catherine P Leith, Brad S Kahl, Kyungmann Kim, Shigeki Miyamoto, “Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.” Mol Cancer  Res, 2008 Aug;6(8):1356-64.
  27. David Yang, Ken Young, Brad Kahl, Stephanie Markovina, Shigeki Miyamoto, “Prevalence of bortezomib-resistant constitutive NF-κB activity in mantle cell lymphoma.” Molecular Cancer, 2008 May 19;7:40.
  28. Mark V. Mishra, Kheem S. Bisht, Rania Awwad, Aradhana Kaushal, Phuongmai Nguyen, Kristi Muldoon Jacobs, Lunching Sun, Lei Huang, J. Daniel Pennington, Stephanie Markovina, C. Mathew Bradbury, and David Gius, “DNMT1 as a Molecular Target Responding to Oxidative Stress-Induced Multi-Modality Resistant Phenotype in Tumor Cells.” Mol. Can. Res. 2008 Feb;6(2):243-9.
  29. Shelby O’Connor, Stephanie Markovina, Shigeki Miyamoto, (2005) “Evidence for a phosphorylationindependent role for Ser 32 and 36 in proteasome inhibitor-resistant (PIR) IkBa degradation in B cells.” Experimental Cell Research, 307(1):15-25.
  30. Kheem S. Bisht, C. Matthew Bradbury, D. Mattson, Aradhana Kaushal, A. Sowers, Stephanie Markovina, K.L. Ortiz, L.K. Sieck, J.S. Isaacs, M.W. Brechbiel, James B. Mitchell, L.M. Neckers, David Gius. (2003) “Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.” Cancer Research, 63(24):8984-95.
  31. Shervin Karimpour, Junyang Lou, Lilie L. Lin, Luis M. Rene, Lucio Lagunas, Xinrong Ma, Sreenivasu Karra, C. Matthew Bradbury, Stephanie Markovina, Prabhat C. Goswami, Douglas R. Spitz, Kiichi Hirota, Dhananjaya V. Kalvakolanu, J. Yodoi, David Gius. (2002) “Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation.” Oncogene, 21(41):6317-27.
  32. Stephanie Markovina*, C. Matthew Bradbury*, S. Jack Wei, Luis M. Rene, Imran Zoberi, Nobuo Horikoshi, David Gius. (2001) “Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-kappaB activation in HeLa cells occur via a mechanism involving p38 MAP kinase.” Cancer Research, 61(20):7689-96.
  33. S. Jack Wei, Ana Botero, K. Hirota, C. Matthew Bradbury, Stephanie Markovina, Andre Laszlo, Douglas R. Spitz, Prabhat C. Goswami, J. Yodoi, David Gius. (2000) “Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation.” Cancer Research, 60(23):6688-95

Related PubMed Search: “Markovina S”

(Disclaimer: This listing may not include all articles associated with this faculty member and may include publications related to others with a similar name.)